Results 121 to 130 of about 2,701,407 (295)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Single‐Cell RNA Sequencing of Human Lung Tissues Reveals Metallothionein‐Positive T Cells as a Novel Potential Marker of Susceptibility to Chronic Obstructive Pulmonary Disease

open access: yesAdvanced Science, EarlyView.
Using single‐cell RNA sequencing of lung samples and flow cytometry of peripheral blood, we identified a novel T cell subset with high metallothionein (MT) expression. These MT‐high T cells suppress CD8+ T cell cytotoxicity and are progressively depleted from healthy controls to chronic obstructive pulmonary disease (COPD) patients, positioning them as
Zengqing Liu   +23 more
wiley   +1 more source

Evaluating the Utilities of Foundation Models in Single‐Cell Data Analysis

open access: yesAdvanced Science, EarlyView.
This study delivers the first systematic, task‐level evaluation of single‐cell foundation models across eight core analytical tasks. By benchmarking 10 leading models with the scEval framework, it reveals where foundation models truly add value, where task‐specific methods still dominate, and provides concrete, reproducible guidelines to steer the next
Tianyu Liu   +4 more
wiley   +1 more source

De la Normatividad a la Pedagogía de la Dignidad: La Educación Colombiana ante el Conflicto y la Vulneración de Derechos

open access: yesHorizontes Pedagógicos
Este texto resalta la urgente necesidad de reformar el sistema educativo en Colombia, que enfrenta el desafío del conflicto armado y la violación de derechos en áreas rurales y comunidades étnicas.
Javier Antonio Nova Nova
doaj  

Annulata nova

open access: yes
(Uploaded by Plazi from the Biodiversity Heritage Library) No abstract provided.
openaire   +1 more source

Novas tecnologias para... novas (?) expografias

open access: yesMuseologia & Interdisciplinaridade, 2012
Os museus têm enfrentado, nos últimos anos, grandes desafios para sobreviver em um mundo onde as fontes de informação e as possibilidades de lazer são inúmeras. E é geralmente por isso, para atrair o público, em especial o público jovem, que os museus têm buscado utilizar novas ferramentas expográficas, que tornem a mostra mais atrativa e motivadora ...
openaire   +4 more sources

DOT1L Drives Endothelial‐to‐Mesenchymal Transition and Fibrotic Vascular Remodeling via H3K79 Methylation

open access: yesAdvanced Science, EarlyView.
DOT1L as a central epigenetic regulator of EndoMT and pulmonary fibrosis. Acting as an early epigenetic switch, it translates TGFβ–SMAD signaling into H3K79me2‐mediated chromatin remodeling, selectively activates fibrosis‐related genes, and primes ECs for rapid mesenchymal transition.
Yaofeng Wang   +11 more
wiley   +1 more source

NOVAS TAREFAS E NOVAS FORÇAS

open access: yesGerminal: Marxismo e Educação em Debate, 2014
<!--[if gte mso 9]><xml> <o:DocumentProperties> <o:Revision>0</o:Revision> <o:TotalTime>0</o:TotalTime> <o:Pages>1</o:Pages> <o:Words>158</o:Words> <o:Characters>901</o:Characters> <o:Company>UFBA</o:Company> <o:Lines>7</o:Lines> <o:Paragraphs>2 ...
openaire   +3 more sources

Sphingomonas paucimobilis‐Driven Epithelial–Endothelial Transition in Adenomyosis Pathogenesis

open access: yesAdvanced Science, EarlyView.
This study identifies epithelial–endothelial transition (EET) as a novel adenomyosis pathogenic mechanism driven by Sphingomonas paucimobilis colonization. Systematic inhibitor experiments validate a TNFα→NF‐κB→MMP signaling cascade essential for EET. Critically, bacterial culture supernatant fails to induce pathological changes, demonstrating viable ...
Peigen Chen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy